Proteinuria Therapeutics Market by Product and Geography - Global Forecast & Analysis 2019-2023

Global Proteinuria Therapeutics Market: About this market

Technavio’s proteinuria therapeutics market analysis considers sales from ACE inhibitors, ARBs, and other therapeutic products. Our analysis also considers the sales of proteinuria therapeutics in Asia, Europe, North America, and ROW. In 2018, the ACE inhibitors segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the prevention of an enzyme in the body from producing angiotensin II, which narrows the blood vessels will play a significant role in the ACE inhibitors segment to maintain its market position. Also, our global proteinuria therapeutics market report looks at factors such as recent approvals and launch of advanced urinalysis diagnostic kits, increasing prevalence of associated risk factors, and growing geriatric population. However, lack of curative therapies, adverse effects of available therapeutics, and stringent regulations may hamper the growth of the proteinuria therapeutics industry over the forecast period.

Global Proteinuria Therapeutics Market: Overview

Increasing prevalence of associated risk factors

Proteinuria is a condition in which urine contains an abnormal amount of protein. This condition can be a sign of damage within the kidneys and CKD: the latter can result from diabetes as well as high blood pressure hypertension. Proteinuria can be caused by diseases that do not involve the kidneys, such as multiple myeloma and others, such as, AIDS, lupus, and rheumatoid arthritis, which also cause inflammation in the kidneys. Globally, the prevalence of all these diseases and infections is very high and is increasing continuously. This multifactorial etiology of the condition increases the demand for treatment options and, thus, drives the growth of the market at a CAGR of almost 3% during the forecast period.

Introduction of smartphone-based diagnosis and treatment

Advances in technology help in increasing the adherence of patients to treatment and, thus, obtain effective and quick results. They help in improving the condition of patients in less time. With the recent advances in technology and the proliferation of smartphone-based applications: urinalysis is also providing effective and quick results at a lower cost. Smartphone-based applications are unique as they are autonomous and do not need a specialist to make clinical decisions. Also, changing lifestyles and technological developments are encouraging more people to opt for application-based treatment due to its easy access. This development is expected to have a positive impact on the overall market growth.

For the detailed list of factors that will drive the global proteinuria therapeutics market during the forecast period 2019-2023, click here.

Competitive Landscape

With the presence of several major players, the global proteinuria therapeutics market is moderately fragmented. Technavio’s robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading proteinuria therapeutics manufacturers, that include AbbVie Inc., AstraZeneca Plc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Co. Ltd., and Teva Pharmaceutical Industries Ltd.

Also, the proteinuria therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.


  • Executive summary
  • Scope of the report
    • Preface
      • Table Product overview
    • Currency conversion rates for US$
  • Market landscape
    • Market ecosystem
      • Table Global pharmaceuticals market
      • Table Segments of global pharmaceuticals market
    • Market characteristics
      • Table Market characteristics
    • Market segmentation analysis
      • Table Market segments
  • Market sizing
    • Market definition
      • Table Market definition - Inclusions and exclusions checklist
    • Market sizing 2018
      • Table Market size 2018
    • Market size and forecast 2018-2023
      • Table Global market: Size and forecast 2018-2023 ($ millions)
      • Table Global market: Year-over-year growth 2019-2023 (%)
  • Five forces analysis
    • Table Five forces analysis 2018
    • Table Five forces analysis 2023
    • Bargaining power of buyers
      • Table Bargaining power of buyers
    • Bargaining power of suppliers
      • Table Bargaining power of suppliers
    • Threat of new entrants
      • Table Threat of new entrants
    • Threat of substitutes
      • Table Threat of substitutes
    • Threat of rivalry
      • Table Threat of rivalry
    • Market condition
      • Table Market condition - Five forces 2018
  • Market segmentation by product
    • Table Product - Market share 2018-2023 (%)
    • Comparison by product
      • Table Comparison by product
    • ACE inhibitors - Market size and forecast 2018-2023
      • Table ACE inhibitors - Market size and forecast 2018-2023 ($ millions)
      • Table ACE inhibitors - Year-over-year growth 2019-2023 (%)
    • ARBs - Market size and forecast 2018-2023
      • Table ARBs - Market size and forecast 2018-2023 ($ millions)
      • Table ARBs - Year-over-year growth 2019-2023 (%)
    • Other therapeutics - Market size and forecast 2018-2023
      • Table Other therapeutics - Market size and forecast 2018-2023 ($ millions)
      • Table Other therapeutics - Year-over-year growth 2019-2023 (%)
    • Market opportunity by product
      • Table Market opportunity by product
  • Customer landscape
    • Table Customer landscape
  • Geographic landscape
    • Geographic segmentation
      • Table Market share by geography 2018-2023 (%)
    • Geographic comparison
      • Table Geographic comparison
    • North America - Market size and forecast 2018-2023
      • Table North America - Market size and forecast 2018-2023 ($ millions)
      • Table North America - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in North America
    • Europe - Market size and forecast 2018-2023
      • Table Europe - Market size and forecast 2018-2023 ($ millions)
      • Table Europe - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Europe
    • Asia - Market size and forecast 2018-2023
      • Table Asia - Market size and forecast 2018-2023 ($ millions)
      • Table Proportion of geriatric population in Asia 2009 and 2018 (% of the total population)
      • Table Asia - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in Asia
    • ROW - Market size and forecast 2018-2023
      • Table ROW - Market size and forecast 2018-2023 ($ millions)
      • Table ROW - Year-over-year growth 2019-2023 (%)
      • Table Top 3 countries in ROW
    • Key leading countries
      • Table Key leading countries
    • Market opportunity
      • Table Market opportunity
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Prevalence/incidence of associated risk factors of proteinuria
      • Table Growth of geriatric population 2009-2018 (%)
    • Market challenges
      • Table Side effects of ACE inhibitors used for the treatment of proteinuria
      • Table Impact of drivers and challenges
  • Market trends
    • Introduction of smartphone-based diagnosis and treatment.
    • Advent of novel therapies
    • Increasing awareness about renal disorders
  • Vendor landscape
    • Overview
      • Table Vendor landscape
    • Landscape disruption
      • Table Landscape disruption
    • Competitive scenario
  • Vendor analysis
    • Vendors covered
      • Table Vendors covered
    • Vendor classification
      • Table Vendor classification
    • Market positioning of vendors
      • Table Market positioning of vendors
    • AbbVie Inc.
      • Table AbbVie Inc. - Vendor overview
      • Table AbbVie Inc. - Business segments
      • Table AbbVie Inc. - Organizational developments
      • Table AbbVie Inc. - Geographic focus
      • Table AbbVie Inc. - Key offerings
      • Table AbbVie Inc. - Key customers
    • AstraZeneca Plc
      • Table AstraZeneca Plc - Vendor overview
      • Table AstraZeneca Plc - Business segments
      • Table AstraZeneca Plc - Organizational developments
      • Table AstraZeneca Plc - Geographic focus
      • Table AstraZeneca Plc - Key offerings
      • Table AstraZeneca Plc - Key customers
    • Boehringer Ingelheim International GmbH
      • Table Boehringer Ingelheim International GmbH - Vendor overview
      • Table Boehringer Ingelheim International GmbH - Business segments
      • Table Boehringer Ingelheim International GmbH - Organizational developments
      • Table Boehringer Ingelheim International GmbH - Geographic focus
      • Table Boehringer Ingelheim International GmbH - Segment focus
      • Table Boehringer Ingelheim International GmbH - Key offerings
      • Table Boehringer Ingelheim International GmbH - Key customers
    • Bristol-Myers Squibb Co.
      • Table Bristol-Myers Squibb Co. - Vendor overview
      • Table Bristol-Myers Squibb Co. - Business segments
      • Table Bristol-Myers Squibb Co. - Organizational developments
      • Table Bristol-Myers Squibb Co. - Geographic focus
      • Table Bristol-Myers Squibb Co. - Key offerings
      • Table Bristol-Myers Squibb Co. - Key customers
    • Merck & Co. Inc.
      • Table Merck & Co. Inc. - Vendor overview
      • Table Merck & Co. Inc. - Business segments
      • Table Merck & Co. Inc. - Organizational developments
      • Table Merck & Co. Inc. - Geographic focus
      • Table Merck & Co. Inc. - Segment focus
      • Table Merck & Co. Inc. - Key offerings
      • Table Merck & Co. Inc. - Key customers
    • Novartis AG
      • Table Novartis AG - Vendor overview
      • Table Novartis AG - Business segments
      • Table Novartis AG - Organizational developments
      • Table Novartis AG - Geographic focus
      • Table Novartis AG - Segment focus
      • Table Novartis AG - Key offerings
      • Table Novartis AG - Key customers
    • Pfizer Inc.
      • Table Pfizer Inc. - Vendor overview
      • Table Pfizer Inc. - Business segments
      • Table Pfizer Inc. - Organizational developments
      • Table Pfizer Inc. - Geographic focus
      • Table Pfizer Inc. - Segment focus
      • Table Pfizer Inc. - Key offerings
      • Table Pfizer Inc. - Key customers
    • Sanofi
      • Table Sanofi - Vendor overview
      • Table Sanofi - Business segments
      • Table Sanofi - Organizational developments
      • Table Sanofi - Geographic focus
      • Table Sanofi - Segment focus
      • Table Sanofi - Key offerings
      • Table Sanofi - Key customers
    • Takeda Pharmaceutical Co. Ltd.
      • Table Takeda Pharmaceutical Co. Ltd. - Vendor overview
      • Table Takeda Pharmaceutical Co. Ltd. - Business segments
      • Table Takeda Pharmaceutical Co. Ltd. - Organizational developments
      • Table Takeda Pharmaceutical Co. Ltd. - Geographic focus
      • Table Takeda Pharmaceutical Co. Ltd. - Key offerings
      • Table Takeda Pharmaceutical Co. Ltd. - Key customers
    • Teva Pharmaceutical Industries Ltd.
      • Table Teva Pharmaceutical Industries Ltd. - Vendor overview
      • Table Teva Pharmaceutical Industries Ltd. - Business segments
      • Table Teva Pharmaceutical Industries Ltd. - Organizational developments
      • Table Teva Pharmaceutical Industries Ltd. - Segment focus
      • Table Teva Pharmaceutical Industries Ltd. - Key offerings
      • Table Teva Pharmaceutical Industries Ltd. - Key customers
  • Appendix
    • Research methodology
      • Table Validation techniques employed for market sizing
    • List of abbreviations
    • Definition of market positioning of vendors
      • Table Definition of market positioning of vendors
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook